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Within the concentration range of 1-20 FM, orthovanadate (Na3VO4) demonstrated a time anddose-dependent inhibition of autocrine growth of the human carcinoma cell lines A549 (lung),
HTB44 (kidney) and DU145 (prostate), as compared to appropriate controls (without Na3VO4).The investigation was conducted by two methods: staining with N-hexa-methylpararosaniline
(crystal violet=CV) or bromide3-(4,5-dimethyltio-azo-2)-2,5-diphenyl-tetrazole (MTT). In
5, 10 and 20 FM of Na3VO4 in serum-free medium, the mean values of these two tests forA549 were approximately 40%, 45% or 65% as compared to the appropriate controls. HTB44
had the greatest opportunity (statistically insignificant) at lower vanadium concentrations
(up to 10 FM), whereas at 20 FM growth inhibition of these cells was approximately 50% of
the controls. DU145 showed approximately 33%, 65% and 98% growth inhibition for 5, 10
and 20 FM of Na3VO4, respectively Additionally, hypothetical curves obtained by aMANOVA test based on the CV results after 72 h incubation with Na3VO4 in serum-freemedium, and an example of a time-dependent effect of Na3VO4 on A549 cells, were alsopresented.
Sodium orthovanadate was also examined for its cytotoxic capabilities, especially its ability
to induce tumor cell apoptosis; the results were compared with the effect of paclitaxel. The
target cells were dyed by differential staining (HOECHST33258 and propidium iodide) after
3 h and 24 h (DU145) or 3 h and 72 h (A549) of incubation with the vanadium compound.
Contrary to the two cancer cell lines (viable, apoptotic or necrotic in experimental conditions),
the renal HTB44 cells were insensitive up to 15 FM Na3VO4 concentrations. After 3 hincubation with Na3VO4, both lung (A549) and prostate (DU145) cancer cells showed a slightbut significant reduction in the percentage of viable cells, and an increased amount of
apoptotic cells. In contrast to the lung cells, DU145 prostate cells after 24 h were more
sensitive to paclitaxel than to sodium orthovanadate. In the case of lung cells, the time of
incubation was prolonged (to 72 h) to allow for a study of the effect of orthovanadate in
greater detail. After 72 h of incubation with Na3VO4 or paclitaxel, A549 showed a similarlevel of viable cells (25-32% of total cultured cells); however, the percentage of apoptotic
cells was higher in the case of A549 cells  ca 36% for both drugs, but the concentration of
Na3VO4 was significantly greater than paclitaxel levels.
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One of the dietary microelements, vanadium, is
essential for the development and growth of some
organisms (ALMEDEIDAet al. 2001; DOMINGO 1996;
FRENCH & JONES 1993). Both organic and inor-
ganic vanadium complexes show numerous bio-
logical activities (CRANS et al. 2004; MUKHERJEE
et al. 2004), often with contrasting effects depend-
ing on the type of vanadium ligands, total dose,
route and duration of administration, and animal
strain or cell line used in experiment. The objec-
tive of investigations and the final answer to scien-
tific questions are both very important. The ability
to normalize some clinical and biochemical symp-
toms of diabetes (both in human patients and ex-
perimental animals) is the best known and most
widely investigated effect of vanadium (THOMPSON
& ORVIG 2006; DOMINGO 2000; GOLDFINE et al.
2000; DABROS et al. 2006; KORDOWIAK et al.
2002; KORDOWIAK et al. 2004).
Moreover, vanadium complexes are used as anti-
tumor drugs (BAN et al. 2000; EVANGELOU et al.
1997; MOLINUEVO et al. 2004; ZHANG et al. 2001;
WOZNIAK & BLASIAK 2004; SCRIVENS et al. 2003),
however, other authors (e.g. ZHANG et al. 2002;
RODRIGUEZ-MERCADO et al. 2003, SHI et al. 2004;
SAKAI 1997; DING et al. 1999) do not agree with
this point of view and have suggested a contrary
action of different vanadium compounds. In pre-
vious experiments we noted that three organic va-
nadium [V(IV)] derivatives: bis(maltolato)oxo-
vanadium(IV), bis(kojato)oxovanadium(IV) and
bis(2,2’–bipy- ridine)oxovanadium(IV) sulphate
resulted in similar, progressive H-35 cell growth
and proliferation rate inhibition in the range
0.5-5.0 FM of appropriate vanadium salts in the
medium (DABROS et al. 2003; DABROS et al. 2004).
Vanadyl sulphate [V(IV)] or vanadate[V(V)], how-
ever, in concentrations approximately six times
greater than that of organic complexes, induced a
similar effect (KORDOWIAK et al. 2007).
It seemed interesting to study the effect of two
inorganic vanadium salts: vanadyl sulphate and
orthovanadate (LIGEZA et al. 2006), on three hu-
man epithelial cancer cell lines (A549, HTB44,
DU145). Vanadyl sulphate triggers the autocrine
growth of these cells in a time- and dose-
dependent manner (HOLKO et al. 2008). This pa-
per discusses the influence of sodium orthovana-
date under experimental conditions in which the
vanadium compound in the form of an anionic ion
[V(V)] acts as an analog of phosphorus com-
pounds and participates in metabolic pathways of
lipids and carbohydrates (ALMEDEIDA et al. 2001;
DOMINGO 1996), affecting the activities of ki-
nases and phosphorylases (BAN et al. 2000; SAKAI
1997; SCRIVENS et al. 2003).
Material and Methods
2.1 Reagents
Dulbecco’s Modified Eagle’s Medium (DMEM),
Minimal Essential Medium (MEM), F12 medium,
glucose, L-glutamine, trypsin, tylosine, EDTA, al-
bumin, penicillin, streptomycin, crystal violet
(CV) (N-hexamethylpararosaniline), MTT [bro-
mide3-(4,5-dimethyltio-azo-2)-2,5-diphenyl-tetrazole],
HOECHST 33258 (bisbenzimid) and propidium
iodide (PI) were purchased from Sigma Chemical
Company (St Louis, USA). Sodium orthovanadate
was obtained from Aldrich Chem. Comp. Inc. Bo-
vine serum (FBS) was obtained from Biowest,
South American Origin. All other reagents were
purchased as analytical grade from Polish Rea-
gents POChem Gliwice, Poland.
2.2 Cell Culture
The human tumor epithelial cell lines A549 (lung),
HTB44 (kidney) and DU145(prostate) were used as
target cells. The A549, HTB-44 cells were ob-
tained from Institute of Immunology and Experi-
mental Therapy Wroc³aw, Poland. DU145 were
purchased from American Type Culture Collec-
tion (ATCC). The stock cultures for DU145, A549
were maintained in DMEM supplemented with
10% FBS, 2mM L-glutamine, 0.45% glucose,
penicillin (100 units/ml) and streptomycin (100
Fg/ml). HTB-44 cells stock culture was main-
tained in MEM supplemented with 1 mM sodium
pyruvate and 1% non-essential amino acids. The
cells were passaged 2-3 times per week using
0.05% trypsin solution with 0.02% EDTA in buff-
ered physiological salt (PBS) without Ca2+ and
Mg2+.
2.3 Cell proliferation and metabolic activity assays
The target cells were seeded on 96-well plates at
a concentration of 3·103 cell/well in (DMEM or
MEM), supplemented with 100 I.U./ml penicillin
and 100 mg/ml streptomycin in the presence of
10%FBS. Following 24h incubation the culture
medium was replaced with serum-free DMEM/F12
(1:1) supplemented with 5% albumin, 5Fg/ml trans-
ferrin, 0.3 mg/ml L-glutamine, 10 Fg/ml tylosine,
2 ng/ml of sodium selenite and 1000 units/ml of
penicillin and 100 mg/ml streptomycin. After the
following 48h, the medium was replaced twice by
serum-free DMEM/F12, and next with the same
liquid containing Na3VO4 (in concentration range
0.5-20 FM). The incubation was continued for the
subsequent 72 h at 37 oC. The modified crystal vio-
let staining method (CV) (GILLIES et al. 1986) and
the MTT tetrazolium assay (MTT) (Mosmann
1983) were used to determine the effect of the va-
nadium compound on the proliferation together
with metabolic activity of target cells. The absor-
bance was measured using a Tecan multiscan plate
reader. Ten replicate wells were used for each ex-
periment. The results were monitored by the Ma-
gellan 3 program. The influence of the vanadium
compound was expressed as a decrease in cell
growth relative to the control. MTT and CV results
are presented as: % of control growth (Fig 2):
(Ai-A0)/(Ac-A0) x 100, or % of growth inhibition
(% GI) = 1 - (Ai-A0)/(Ac-A0) x 100; A0, Ac, Ai – av-
erage values of absorbance at 540 nm (CV),
570 nm (MTT) of control sample at the start of ex-
periment (A0), the control sample after 72 h of in-
cubation (Ac) and after 72h incubation with
Na3VO4 (Ai).
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2.4.Assessment of cell viability
A differential staining method was used to inves-
tigate the effect of Na3VO4 on viability of the can-
cer cell lines. The cells were seeded on 24-well
plates at a density of 12·103 per well in 0.8 ml
DMEM or MEM with 10% FBS. After 48 h, the
medium was replaced twice by serum-free me-
dium, and the cells were exposed to 20 FM con-
centration of Na3VO4 After 3 h, 24 h, 72 h and
120 h of incubation the cells were stained with
HOECHST 33258 and propidium iodide (PI) (at
concentration 5 Fg/ml and 1 Fg/ml, respectively).
After 15 min the investigated cultures were di-
rectly examined on plates with an epifluorescence
microscope (Olympus IX-50) equipped with ap-
propriate filters. Two excitation filters were used:
one allowed for excitation of both dyes, and the
other only for PI excitation. The Image J software
was used for image processing (merging RGB
channels, enhancing contrast and sharpening) and
the quantitative analysis of the processed pictures
(cell counting). This allowed for an estimation of
the fraction of necrotic cells (PI/DNA signal), vi-
able cells (HOECHST33258/DNA signal) and
apoptotic cells (HOECHST33258/DNA signal
with morphological changes). 50 nM paclitaxel
(BERGSTRALH & TING 2006) was used as the posi-
tive control in proapoptotic examination of
Na3VO4. Each experiment was repeated at least six
times; images that presented more than 100-600
cells were used in the quantitative analysis.
2.5 Statistical analysis
The results were expressed as mean ± standard
error (SEM). Differences between the vanadium-
treated cells and control cells were evaluated sta-
tistically using the Wilcoxon’s matched pair test
according to the Statsoft Statistica program
(MOTULSKY 1996, Statsoft Statistica manuals). P
values lower than 0.05 were considered signifi-
cant. CV and MTT results were used to obtain a
hypothetical dose dependent curve (Logistic
model origin MANUAL), the equation describing
the curve was used to calculate the IC50 value. The
statistical analysis of the obtained dose-dependent
curves was performed by MANOVA according to
the Statsoft Statistica software.
Results
The exposure of the A549, HTB44 and DU145
cells to the orthovanadate resulted in time and
dose-dependent suppression of proliferation as
compared to appropriate controls (without the va-
nadium in the culture medium). The dependence
on time is presented in Table 1. The effects of so-
dium orthovanadate (Na3VO4) on autocrine
growth of three human cancer epithelial cell lines:
A549, HTB44 and DU145 are shown in Figure 1.
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Table 1
Time-dependent influence of orthova-
nadate on growth of investigated hu-
man carcinoma cell lines. The sodium
orthovanadate concentration required
for 50 % inhibition of control’s growth
(IC50) were obtained from crystal violet
staining results (CV) and MTT reduc-
tion method results
Cell lines
Time of
incubation [h]
IC50 SD [FM]
CV MTT
A549
(lung)
72 9.55"0.81 9.59"2.59
120 2.89"0.42 2.61"0.31
HTB44
(kidney)
72 19.50"1.50 20.03"2.13
120 >15.0 14.63"5.88
DU145
(prostate)
72 9.37"0.42 5.06"1.78
Fig. 1. The percent of control growth inhibition of cancer cell lines (A549, HTB44, DU145) by Na3VO4 determined by modified
crystal violet staining method (A) and MTT test (B) after 72h of incubation in serum-free medium (DMEM/F12). ns – non
significant (P>0.05) in comparison with the control sample (without Na3VO4). * 0.01<P <0.05; ** 0.001<P<0.01. The bar,
(seen last in part B), which represents an orthovanadate concentration greater than 100% in 20 FM after 72 h, indicates that
despite growth inhibition, appropriate doses of the salt exert a cytotoxic effect (at the time of incubation the cell count is less
than at the time of vanadium addition).
The results obtained by two different methods,
crystal violet (A) and MTT (B) were dependent on
the type of investigated cells. In the case of A549
cells, both methods showed a similar effect of
Na3VO4. The percent of control growth inhibition
(%GI) of A549 cells at 10 FM and 20 FM concen-
trations of vanadium were about 45% and 65% re-
spectively, regardless of the method used. The
level of growth inhibition of the DU145 cells de-
termined by the CV method (54% and 91%, at the
concentration of 10 FM and 20 FM, respectively)
was much lower than that demonstrated in the
MTT test (84% and 156% at concentration 10 FM
and 20 FM, respectively). No statistically signifi-
cant differences (in comparison with the control
samples) were observed at the vanadate concentra-
tion of 0.5 FM determined by the CV method,
while MTT indicated 25% inhibition of cell
growth of A549. A significant effect of orthovana-
date on the growth of the HTB44 cells was ob-
served at a concentration of 20 FM. The values of
the percentage of growth inhibition for the HTB44
cells incubated with 20 FM vanadium were 52%
and 49% for CV and MTT methods, respectively.
Hypothetical curves obtained from MTT and CV
results and tested by MANOVA are presented in
Figure 2. Figure 2A shows hypothetical dose-
response curves obtained from CV results after
72h incubation with Na3VO4 in serum-free me-
dium. These confirm results of MTT and CV,
showing the dependences of the type of examined
cells on the magnitude of vanadium impact across
the full of range of vanadium concentration. Fig-
ure 2B shows an example of a time-dependent ef-
fect of Na3VO4 on the A549 cells. If the time of
action is prolonged, the curves move downwards
toward low Na3VO4 concentrations, against mini-
mum differences in the incline of these curves.
This indicates that the time-dependence observed
in MTT and CV analyses is statistically significant.
Sodium orthovanadate was also examined for its
cytotoxic potential, especially its ability to induce
tumor cell apoptosis. The target cells were stained
after 3 h and 24 h (DU145) or 3 h and 72 h (A549)
of incubation with the vanadium compound. The
renal HTB44 cells were insensitive to the investi-
gated Na3VO4 concentrations, therefore, Figures 3
and 4 illustrate only the results for 20FM of the va-
nadium in comparison with 50 nM of paclitaxel, a
known cytotoxic drug (BERGSTRALH & TING
2006) with proapoptotic action for two cancer cell
lines: (A549 and DU145 – viable, apoptotic or ne-
crotic under the experimental conditions). Apop-
totic cells were clearly distinguishable by their
characteristic morphology (cytoplasmic blebbing,
cell shrinkage, nuclear condensation and fragmen-
tation). Such morphological alterations were
found in all the investigated cell cultures; how-
Fig. 2. Hypothetical dose- response curves obtained from the
results of CV. (A) Dose- response curves for the sodium
orthovanadate effect on carcinoma cells after 72 h
incubation in a serum- free medium. (B) Time-dependence
of sodium orthovanadate effect on the A549 cells.
Fig. 3. The cytotoxic effect of sodium orthovanadate (OV) on
cell viability of the DU145 prostate carcinoma cell line
determined by differential staining (HOECHST 33258/PI)
after 3 h and 24 h of incubation with 20 FM OV.
* 0.01<P<0.05 as compared to the controls (without
Na3VO4 or paclitaxel).
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ever, in the case of control cultures they did not in-
volve more than 10% of the total cell population.
After 3 h incubation with orthovanadate both lung
(A549) and prostate (DU145) cancer cells showed
slight but significant reductions in the percentage
of viable cells and an increased number of apop-
totic (A549) or necrotic (DU145) cells. In contrast
to the lung cells, prostate cells DU145 were more
sensitive to paclitaxel than to sodium orthovana-
date. After 24 h of incubation with orthovanadate,
81% of the prostate cancer cells survived (Fig. 3).
Incubation of these cells with paclitaxel caused a
30% decrease in viability. The time of incubation
was prolonged in the case of lung cells (these cells
grow slower than DU 145), to allow for a more de-
talied investigation of the effect of orthovanadate.
After 72 h of incubation with orthovanadate or pa-
clitaxel, the A549 cells showed a similar percent-
age of viable cells (25-32% of the total cultured
cells) (Fig. 4). The percentage of apoptotic cells in
the case of A549 reached approximately 36% for
both drugs.
4. Discussion
Although the particular mechanisms of the ef-
fect of vanadium on living cells has not been eluci-
dated to date, several possibilities have been
proposed by investigators, such as inhibition of
protein phosphatases (ZHANG et al. 2003; VINALS
et al. 2001), an increased activity of phosphodies-
terases (KAWABE et al. 2006), protein kinases in-
volved in cell growth and development (BAN et al.
2000; ZHANG et al. 2003; SCRIVENS et al. 2003;
DING et al. 1999; VINALS et al. 2001), DNA dam-
age (ZHANG et al. 2002; RODRIGUEZ-MERCADO
et al. 2003; WOZNIAK & BLASIAK 2004; IVANCSITS
et al. 2002), changes in genes and synthesis of
regulatory proteins (CAPELLA et al. 2002; VINALS
et al. 2001) or generation of reactive oxygen spe-
cies and oxidative stress (MOLINUEVO et al. 2004;
ZHANG et al. 2001; ZHANG et al. 2003; SHI et al.
2004; CAPELLA et al. 2002; DING et al. 1999).
These suggestions address many different sites
and modes of action, some of them being synergis-
tic; however, certain authors hold their own views
that some of these effects are mutually exclusive.
For example, SCRIVENS et al. (2003) suggest that
the anti-neoplastic potential of bisperoxyvana-
dium analogues is associated with phosphatase in-
hibition in the entire cells and does not appear to
result from DNA damage or oxidative stress. Con-
trary to this opinion, IVANCSITS et al. (2002) pro-
pound that VO43- is a phosphate analogue and thus
may interfere with phosphate-containing en-
zymes, being involved in DNA repair mecha-
nisms. According to these authors, vanadate is
genotoxic per se and may act as an indirect geno-
toxic agent. In vitro vanadate may effectively in-
duce DNA breaks in human fibroblasts (IVANCSITS
et al. 2002).
In our opinion, the mode of action of vanadium
derivatives depends on the employed models and
experimental conditions, total doses and time of
action, as well as on the kinds of complexes. The
latter issue is an interesting problem associated
with differences in the mode of action of various
vanadium derivatives, i.e. the effect of the vanadium-
complexing ligands themselves on the structure
and function of intracellular organelles (DABROS
& KORDOWIAK 2007). The employed ligands af-
fect the cells in a manner that is entirely different to
the effect of complete (vanadium including) com-
plexes; moreover, they alone evoke different
changes, e.g. in intracellular structures. In addi-
tion, if the degree of the effects of various vana-
dium compounds are analyzed, differences in their
absorption should be taken into consideration, the
ease of dissociation in the environment in which
they act (e.g. the gastrointestinal tract, tissue, cul-
tured cells), as well as changes in the valence of va-
nadium that crosses the cellular membrane barrier
[e.g. from V(IV) to V(V)]. Of great significance is
also the model system employed in the experi-
ments. For example, two chemical analogues, such
as bis(maltolato)oxovanadium (BMOV) and
bis(kojato)oxovanadium (BKOV), are diametri-
cally different in their effect as antidiabetic
“drugs” in vivo, but have the same effect on growth
and proliferation when added to the culture me-
dium of H35-19 cells (DABROS et al. 2004 a, b).
Fig 4. The cytotoxic effect of sodium orthovanadate (OV) on
cell viability of the A549 lung carcinoma cell line
determined by differential staining (HOECHST 33258/PI)
after 3h and 72h of incubation with 20 FM OV.
* 0.01<P<0.05 as compared to the controls (without
Na3VO4 or paclitaxel).
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The previously observed growth inhibition of
the rat hepatoma cancer cell line H35-19 by or-
ganic and inorganic vanadium compounds (DABROS
et al. 2003; DABROS et al. 2004, KORDOWIAK et al.
2007) prompted us to carry out experiments with
three human epithelial cancer cell lines. The re-
sults with vanadyl sulphate (HOLKO et al. 2008)
were promising, therefore we decided to study the
effects of orthovanadate (the second vanadium salt
most often used in human volunteers CRANS et al.
2004; THOMPSON & ORVIG 2006) on the human
carcinoma cell lines i.e. A549 (lung), HTB44 (kid-
ney) and DU145 (prostate), In previous investiga-
tions we observed growth inhibition in a concentra-
tion range of 1-20 FM Na.3VO4 (LIGEZA et al.
2006). The viability of the three cell lines investi-
gated under the same conditions was impaired by
this vanadium salt in 87%, 56% and 49% respec-
tively. Based on the experimental results used for
the MANOVA test, we obtained a hypothetical
time- and dose-response, logistic models of two
curves. These curves showed a significant differ-
ence in the response of cancer cells to an increased
concentration or a prolonged time of action of the
drug. The development of hypothetical curves
confirmed the variability of the response of vari-
ous cell lines to the same orthovanadate concentra-
tion values (Fig. 2A) and the statistical significance
of the prolonged exposure time of these cells to the
investigated vanadium compound (Fig. 2B). Based
on the hypothetical curves, the authors obtained
the values of IC50 ± SD presented in Table 1. In all
the employed concentrations, the greatest value
was demonstrated by the renal HTB44 cell line.
This study additionally presents a comparison of
the effect of the vanadium salt or paclitaxel on the
viability of the investigated cells, determined by
differential staining (HOECHST33258, PI) method
after 3 h and 24 h or 3h and72 h of incubation in a
serum free medium and compared to appropriate
controls incubated under the same experimental
conditions without Na.3VO4 or paclitaxel in the
medium. As follows from our observations, the ac-
tion of the vanadium salt has a stronger influence
on the lung [A549] and prostate [DU145] cell lines
than on the renal [HTB44] carcinoma cells. The re-
nal cells showed the greatest opportunity against
orthovanadate under the same experimental condi-
tions. An exact comparison of the effect of or-
thovanadate on the lung and prostate human
carcinoma cell lines was performed after the same
duration of action of the drug, i.e. 3h. After this
time, the A549 cell line, in contrast to DU 145
cells, showed a significantly higher percent of
apoptotic cells as compared with appropriate con-
trols. In order to perform a more accurate assess-
ment of the action of orthovanadate on the lung
A549 carcinoma cells and to compare it to the ef-
fect of paclitaxel, a well-known specific inductor
of apoptosis (BERGSTRALH & TING 2006), the
time of incubation was increased three-fold (from
24h to 72h). In this case the effect of both drugs
was similar, however, Na3VO4 had to be used in a
concentration that was approximately 400 times
higher than the level of paclitaxel. Similar effects
were previously obtained with vanadyl sulphate in
the same experimental conditions (HOLKO et al.
2008), but the VOSO4 concentration in the serum
free medium must be 1.5 times higher as compared
to orthovanadate to induce similar effects in the in-
vestigated cells.
In conclusion, orthovanadate (and previously
studied vanadyl sulphate) is capable of inhibiting
in culture the growth of some human epithelial
cancer cells. However, vanadium salts must be
used in concentrations higher than those of pacli-
taxel; these are also capable of inducing death of
cancer cells by apoptosis. The authors suggest that
by induction of oxidative stress and/or inhibition
of phosphatases, orthovanadate affects the activi-
ties of protein kinases, which are adjusted during
cell growth. To confirm this theory, detailed inves-
tigations must be carried out in the future. An addi-
tional question is whether the anti-proliferative
effect of some vanadium compounds will allow for
employing such compounds as “auxiliary drugs”
in certain types of cancer.
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